⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights

Company

CRO Partners
Contact Us
Privacy Policy

© 2025 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Survodutide (Survodutide) | Accelerate Your Fibrosis Research

Home/Drugs/Survodutide

Survodutide

Survodutide

Phase 3

Sponsor: Boehringer Ingelheim

Indication: MASH

Mechanism of Action

GLP-1/Glucagon Dual Agonist

Target: GLP-1Target: Glucagon

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT06200467

A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity

Phase:PHASE1Org:Boehringer Ingelheim

RECRUITING

Relevant Publications (PubMed)

Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP-1R agonist survodutide in mice.

Long F, Challa TD, Efthymiou V et al.

Diabetes Obes Metab2025 Dec 12

Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed.

Martínez-Castelao A, Górriz JL, Fernández-Fernández B et al.

J Clin Med2025 Nov 23

Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.

Abdelrahman RM, Musa TH, Arbab IA et al.

J Obes2025

Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial.

Validated Models

This drug has been validated in the following preclinical models:

NCT07221591

A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body

Phase:PHASE1Org:Boehringer Ingelheim

COMPLETEDNCT04667377

A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight

Phase:PHASE2Org:Boehringer Ingelheim

RECRUITINGNCT06632444

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Phase:PHASE3Org:Boehringer Ingelheim

ACTIVE_NOT_RECRUITINGNCT06066528

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

Phase:PHASE3Org:Boehringer Ingelheim

View all trials on ClinicalTrials.gov

Platz E, Kaplan LM, le Roux CW et al.

JACC Heart Fail2025 Nov 3

Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.

Wharton S, le Roux CW, Bozkurt B et al.

Diabetes Obes Metab2025 Nov 11

View more on PubMed